Cite
HARVARD Citation
Johnston, S. et al. (2023). P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes. Breast. pp. S22-S23. [Online].